AST Lab Test: Normal Range vs. Functional Optimal Range

What AST Actually Measures

AST is an enzyme that transfers an amino group from aspartate to alpha-ketoglutarate, producing oxaloacetate and glutamate. Every nucleated cell in the body contains some AST, but concentrations are highest in the liver, heart, and skeletal muscle [1]. When cells in any of these tissues are damaged or destroyed, AST leaks into the bloodstream and your measured level rises.

This lack of organ specificity is the single most important thing to understand about your AST result. A high number does not automatically mean liver disease. The American College of Gastroenterology (ACG) 2017 clinical guideline on evaluation of abnormal liver chemistries states that AST elevation should always be interpreted alongside ALT, alkaline phosphatase, bilirubin, and clinical context before attributing it to a hepatic cause [2]. A 2021 retrospective cohort study in BMJ Open (N=10,928) found that isolated AST elevation without a concurrent ALT rise was attributable to non-hepatic causes in over 38% of cases [3].

Two isoforms exist. Cytoplasmic AST (cAST) and mitochondrial AST (mAST). Mild hepatocyte irritation releases the cytoplasmic fraction first. Severe necrosis releases both, which is why AST can spike disproportionately higher than ALT in acute, destructive processes like ischemic hepatitis or acetaminophen toxicity [1].

Standard Reference Range: Where Labs Draw the Line

Most commercial laboratories in the United States report an AST reference range of 10 to 40 U/L for adults, though slight variations exist between platforms. Quest Diagnostics uses 10 to 40 U/L. Labcorp uses 10 to 37 U/L for females and 10 to 40 U/L for males. These ranges are derived from population-based 95th-percentile cutoffs, meaning they capture the middle 95% of results from a reference population that may include people with undiagnosed fatty liver disease, subclinical alcohol use, or obesity [4].

That population contamination matters. A landmark 2002 study published in Hepatology re-derived aminotransferase upper limits after excluding individuals with hepatitis C, hepatitis B, alcohol use exceeding 20 g/day, and BMI above 25 [4]. The recalculated upper limit of normal for AST dropped to 31 U/L for men and 23 U/L for women. The ACG guideline adopted gender-specific cutoffs of 33 U/L (male) and 25 U/L (female) based on this and subsequent data [2].

Age affects AST as well. Neonates and infants run AST levels two to three times the adult range due to normal hepatocyte turnover during growth, with values declining to adult levels by approximately age 15 [5]. In adults over 60, AST may trend slightly lower because of reduced muscle mass and lower baseline hepatocyte turnover.

Functional Optimal Range: A Tighter Window

Functional medicine practitioners and some integrative endocrinologists use a narrower band of roughly 15 to 26 U/L as a "functional optimal" range for AST. The premise is that values within the standard range but near the upper boundary may already reflect subclinical hepatic stress, especially if paired with rising ALT, elevated GGT, or metabolic risk factors like insulin resistance [6].

Is there published evidence supporting a tighter range? Several large cohort studies provide indirect support. A 2020 analysis in the Journal of Clinical Medicine (N=14,257,581 Korean adults) found that AST values in the upper quartile of the normal range were associated with a 1.4-fold increased risk of all-cause mortality compared to the lowest quartile, even after adjustment for metabolic confounders [7]. The relationship held for cardiovascular mortality as well.

A 2019 NHANES analysis published in PLOS ONE demonstrated that ALT and AST values within traditional reference ranges but above gender-specific thresholds (AST >26 U/L for women and >31 U/L for men) were independently associated with metabolic-associated steatotic liver disease (MASLD) on ultrasound [8]. So "normal" is not the same as "optimal." A value of 38 U/L passes the standard lab flag. It would not pass a functional screen.

The clinical utility of this tighter window depends on your goals. For a 25-year-old competitive CrossFit athlete who trains six days a week, an AST of 35 U/L is almost certainly exercise-induced and not pathologic. For a sedentary 52-year-old with a waist circumference of 42 inches and fasting glucose of 108 mg/dL, that same 35 U/L warrants a hepatic steatosis workup.

The AST/ALT (De Ritis) Ratio

The De Ritis ratio divides AST by ALT and provides diagnostic texture that neither enzyme alone can offer. In a healthy liver, ALT is predominantly cytoplasmic and clears more slowly, so ALT usually runs slightly higher than AST, yielding a ratio below 1.0 [9].

When the ratio flips above 1.0, it suggests a process beyond simple steatosis. Ratios between 1.0 and 2.0 occur in fibrotic liver disease, cirrhosis, and cardiac injury. A ratio exceeding 2.0 is classically associated with alcoholic hepatitis. A 2003 meta-analysis published in Clinical Gastroenterology and Hepatology found that an AST/ALT ratio above 1 had a positive predictive value of 81% for cirrhosis in patients with chronic hepatitis C [10].

Here is a quick interpretation guide:

• Ratio <1.0 (ALT dominant): typical of MASLD, viral hepatitis without advanced fibrosis, or medication effect
• Ratio 1.0 to 2.0: suspect advancing fibrosis, cirrhosis, or cardiac/muscle source
• Ratio >2.0: strongly suggests alcohol-related liver injury
• Ratio >3.0 with very high AST: consider Wilson disease or fulminant hepatic necrosis

The ratio loses reliability when both values are extremely elevated (above 500 U/L), because both enzymes are released in massive quantities regardless of cause [9].

Common Causes of Elevated AST

AST can rise for hepatic and non-hepatic reasons. Separating the two requires pattern recognition.

Hepatic causes include MASLD (the most common cause of mild chronic elevation in the U.S., affecting roughly 30% of adults [11]), alcohol-associated liver disease, viral hepatitis B and C, autoimmune hepatitis, drug-induced liver injury (acetaminophen, statins, amiodarone, isoniazid), hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency [2].

Non-hepatic causes include vigorous exercise (particularly eccentric-loading activities such as downhill running or heavy resistance training), myocardial infarction, rhabdomyolysis, hemolysis, thyroid disease, celiac disease, and adrenal insufficiency [2][12]. A 2013 study in the British Journal of Sports Medicine found that AST rose an average of 69% above baseline within 24 hours of a marathon, returning to normal by day 7 [12].

A single elevated AST result should always be repeated after removing confounders. The ACG guideline recommends avoiding strenuous exercise for 48 to 72 hours before the repeat draw, limiting acetaminophen, and abstaining from alcohol for at least 72 hours [2]. If the elevation persists on two separate occasions, a stepwise workup begins.

How to Lower AST

Lowering AST means addressing the underlying tissue insult, not treating the number itself. The approach depends on the cause.

For MASLD, weight loss is the most effective intervention. A 2015 prospective study published in Gastroenterology (N=293) showed that a loss of 7% or more of body weight produced histologic resolution of steatohepatitis in 64% of participants and normalized aminotransferases in the majority [13]. Exercise alone, even without weight loss, reduces intrahepatic triglyceride content and can lower AST by 10% to 20% [14].

For alcohol-related elevation, abstinence is the intervention. AST typically normalizes within 2 to 6 weeks of complete cessation in patients without advanced fibrosis [2].

For medication-induced elevation, switching or discontinuing the offending agent is the primary step. With statins, the American Heart Association notes that mild aminotransferase elevation (less than 3 times the upper limit of normal) does not require discontinuation and routine monitoring is no longer recommended [15]. Levels exceeding 3 times the upper limit warrant reassessment.

Specific supplements have modest evidence. Vitamin E at 800 IU/day improved histology in non-diabetic NASH patients in the PIVENS trial (N=247), reducing AST alongside ALT [16]. Omega-3 fatty acids at 2 to 4 g/day showed aminotransferase reduction in a 2016 Cochrane review of 18 trials, though the effect size was small [17].

Coffee consumption of 3 or more cups daily is associated with lower aminotransferases and reduced risk of hepatic fibrosis, per a 2017 meta-analysis of 11 cohort studies published in Alimentary Pharmacology & Therapeutics [18].

When AST Is Too Low

An AST below 10 U/L is uncommon and receives less clinical attention than elevation. Possible explanations include vitamin B6 (pyridoxine) deficiency, since B6 is a required cofactor for the AST transamination reaction [19]. Uremia can also suppress aminotransferase activity; patients on hemodialysis frequently run AST values 15% to 25% below population means [20].

A very low AST is not inherently dangerous. It can, however, mask hepatic injury. A patient with severe B6 deficiency and concurrent liver disease may show a falsely normal or low AST, leading to a missed diagnosis. The AASLD recommends checking a B6 level in patients with unexpectedly low aminotransferases and suspected liver pathology [2].

From a functional perspective, values below 15 U/L may prompt evaluation of B6 status, protein intake, and overall nutritional adequacy. A B6 level below 20 nmol/L (the CDC-defined deficiency threshold) paired with low AST supports supplementation at 25 to 50 mg/day of pyridoxal-5-phosphate [19].

AST in Specific Clinical Contexts

Cardiac injury. AST was one of the original cardiac biomarkers before troponin replaced it. In acute myocardial infarction, AST rises within 6 to 8 hours, peaks at 24 to 48 hours, and normalizes by day 4 to 6. While troponin is now the gold standard, an incidentally elevated AST with a normal ALT and elevated CK should prompt cardiac consideration [1].

Thyroid disease. Both overt hypothyroidism and hyperthyroidism can raise AST. Hypothyroidism reduces bile acid clearance and can produce a mild cholestatic pattern. A 2014 European Journal of Endocrinology study found aminotransferase elevation in 25% of patients with TSH above 10 mIU/L, normalizing with levothyroxine therapy [21].

Exercise-induced elevation. This is arguably the most common benign cause in health-optimizing populations. Creatine kinase (CK) is the best discriminator. If AST is elevated but CK is also markedly elevated and ALT is only mildly elevated, the source is almost certainly skeletal muscle, not liver [12].

Pregnancy. AST normally remains stable or decreases slightly during uncomplicated pregnancy. An AST rise in the third trimester should trigger evaluation for HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), preeclampsia, or acute fatty liver of pregnancy [22].

How to Interpret Your AST Result: A Practical Checklist

Before reacting to your AST number, run through this sequence:

1. Check ALT simultaneously. If both are elevated, a hepatic source is more likely. If AST is elevated but ALT is normal, think muscle, heart, or hemolysis.
2. Calculate the De Ritis ratio. AST ÷ ALT. Below 1.0 favors steatosis or early hepatitis. Above 2.0 favors alcohol.
3. Review exercise history. Any intense training in the preceding 72 hours can confound results.
4. Check CK. Elevated CK with elevated AST and near-normal ALT points to a muscular source.
5. Review medications. Acetaminophen, statins, antiepileptics, antibiotics, and supplements (kava, green tea extract) can raise AST.
6. Assess metabolic risk. BMI, waist circumference, fasting glucose, triglycerides, and hemoglobin A1c determine MASLD probability.
7. Repeat the draw. One abnormal value does not establish chronicity. The ACG requires elevation on two occasions separated by at least 4 weeks before initiating a full workup [2].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASLD recommends screening with the FIB-4 index (using age, AST, ALT, and platelet count) as the initial non-invasive assessment for fibrosis in all adults with metabolic risk factors [23]. A FIB-4 score below 1.3 rules out advanced fibrosis with a negative predictive value exceeding 90%.